

Transarterial Infusion Chemotherapy With and Without Embolisation in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis

Jing Zhao, ^{*1MD}, Dapeng Li, ^{*2MD}, Yue Shi, ^{2MD}, Fengling Shi, ^{2MD}, Chengting Feng, ^{2MD}, Wei Li, ^{2PhD}, Min Tao, ^{2PhD}, Rongrui Liang, ^{2PhD}

Abstract

Introduction: The purpose of this meta-analysis was to compare the efficacy of transarterial chemoembolisation (TACE) and iodised oil infusion chemotherapy without embolisation (TAI) in patients with hepatocellular carcinoma. **Materials and Methods:** We searched for randomised controlled trials, retrospective cohort studies, and two-arm prospective studies that compared the clinical outcomes in patients who received TACE and TAI treatment. Database search was performed through 14 December 2016. Rates of survival and therapy response were compared using odds ratios (OR) with 95% confidence intervals (CI). **Results:** Survival rates and therapy response rates were similar between patients who received TACE and TAI treatments (pooled OR: 1.278; 95% CI, 0.783 to 2.086, $P = 0.327$; and pooled OR: 1.502; 95% CI, 0.930 to 2.426, $P = 0.096$, respectively). **Conclusion:** Our results suggest that treatment intensification by adding embolisation did not increase overall survival and therapy response over TAI in patients with hepatocellular carcinoma.

Ann Acad Med Singapore 2017;46:174-84

Key words: Liver cancer, Liver disease, Transarterial chemoembolisation

¹Department of Radiation Oncology, The Affiliated Hospital of Soochow University, People's Republic of China

²Department of Oncology, The Affiliated Hospital of Soochow University, People's Republic of China

Address for Correspondence: Dr Liang Rongrui, Department of Oncology, The Affiliated Hospital of Soochow University, 188th Shizi Street, Gusu District, Suzhou, Jiangsu Province, 215006, People's Republic of China.

Email: lengbeng@suda.edu.cn

*These authors contributed equally to this work.